Press Coverage

Press Coverage

Research Shows Promising Long-Term Outcomes For New Vascular Graft Treatment

Somahlution recently released results of a study on long-term outcomes in procedures using their vascular graft treatment product, Duragraft. The company, based in Jupiter, Florida, is celebrating the highly encouraging results [...]

Researchers conducted a retrospective, nonrandomized real-world study of 2,436 patients who had CABG with at least one saphenous vein graft. In the cohort, 1,036 were treated with the vascular graft treatment designed to protect [...]

Dr. Haime discusses an abstract about Somahlution DuraGraft during a rapid response session at the 2016 annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS; 1–5 October, Barcelona, Spain) [...]

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]